These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 393377)

  • 1. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Balch CM; Murray D; Presant C; Bartolucci AA
    Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
    Karakousis CP; Didolkar MS; Han T
    Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of malignant melanoma.
    Kroon BB; Nieweg OE
    Ann Chir Gynaecol; 2000; 89(3):242-50. PubMed ID: 11079795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
    Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levamisole as a surgical adjuvant therapy for malignant melanoma.
    Gonzalez RL; Spitler LE; Sagebiel RW
    Cancer Treat Rep; 1978 Nov; 62(11):1703-7. PubMed ID: 365324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy.
    Hamming-Vrieze O; Balm AJ; Heemsbergen WD; Hooft van Huysduynen T; Rasch CR
    Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):795-800. PubMed ID: 19687401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
    Halpern J; Catane R; Biran S; Fuks Z
    Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Carbone PP; Costello W
    Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.